Tuberculosis
Conditions
Interventions
Sponsors
University of California San Francisco
Makerere University College of Health Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. (Site-level) Use standard (multi-day) sputum smear microscopy and/or GeneXpert testing as the primary method of TB diagnosis 2. (Patient-level): Aged =18 years 3. (Patient-level): Initiate evaluation for active pulmonary TB at a community health center (HC IV) enrolled in the study 4. (Provider-level): All providers (e.g., physicians, nurse practitioners, midwives, laboratory staff) (a) aged =18 years; (b) employed by the community health center (HC IV); and (c) involved in the conduct or supervision of health center work related to diagnosis and management of TB
Exclusion criteria
Exclusion criteria: 1. (Site-level) Do not agree to participation 2. (Site-level) Perform sputum smear examination on <150 patients per year (based on 2015 data) 3. (Site-level) Diagnose <15 smear-positive TB cases per year (based on 2015 data) 4. (Site-level) Have on-going economic support program(s) for patients 5. (Patient-level) Have sputum collected for monitoring of response to anti-TB therapy 6. (Patient-level) Have sputum collected as part of active, community-based case finding (e.g., contact tracing, community outreach campaign) 7. (Patient-level) Referred to a study health center for TB treatment after a diagnosis is established elsewhere 8. (Patient-level) Started on TB treatment for extra-pulmonary TB only
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion treated for microbiologically-confirmed TB within two weeks of initial submission of sample for sputum-based testing ;Number initiating treatment for microbiologically-confirmed TB within two weeks of submission of sample for sputum-based testing | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion completing testing;Number diagnosed with microbiologically-confirmed TB*;Proportion diagnosed with microbiologically-confirmed TB*;Number suspected/diagnosed with RIF-resistant TB*;Proportion suspected/diagnosed with RIF-resistant TB*;Time to microbiologically-confirmed TB;Number treated for TB;Proportion treated for TB;Number treated for microbiologically-confirmed TB;Proportion treated for microbiologically-confirmed TB;Proportion with microbiologically-confirmed TB treated;Time-to-treatment of microbiologically-confirmed TB;Patient costs (total costs, direct costs, indirect costs);Intervention arm process metrics;Patient satisfaction with care survey (general satisfaction with care, convenience of services, health facility environment, provider interpersonal skills, provider technical competence);Provider survey (intention, attitudes/beliefs, social norms/expectations, self-efficacy/ behavioral control);Number referred for TB testing;Proportion who receive cash transfer at time of sputum submission;Time to cash transfer | — |
Countries
Uganda
Contacts
Public ContactJillian Kadota
Research Associate
Outcome results
None listed